What is the CDC cutoff for immunity to Hepatitis B (Hep B)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 19, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

CDC Cutoff for Hepatitis B Immunity

The CDC defines protective immunity against hepatitis B as an anti-HBs (antibody to hepatitis B surface antigen) level of ≥10 mIU/mL. 1

Key Testing Parameters

  • Testing method: Use a quantitative assay (such as ELISA) that can detect the protective concentration of ≥10 mIU/mL 1
  • Timing: Perform testing 1-2 months after the final dose of the vaccine series 1
  • Interpretation: Anti-HBs ≥10 mIU/mL indicates protective immunity and the person is considered immune 1

Important Clinical Considerations

Assay Variability

Different laboratory assays have different cutoff values, so the reported anti-HBs level may vary depending on which assay is used. 1 Always refer to the package insert of the specific test being used to determine the actual protective level. 1

Long-Term Protection in Immunocompetent Persons

Immunocompetent individuals who achieve anti-HBs ≥10 mIU/mL after completing the primary vaccine series have long-term protection and do not need further periodic testing or booster doses. 1, 2 This protection persists even if antibody levels subsequently decline below 10 mIU/mL, due to immunologic memory. 3, 4

Special Populations Requiring Different Management

Healthcare personnel (HCP): Should be tested for anti-HBs upon hire or matriculation if they have documentation of complete vaccination. 1 Those with anti-HBs <10 mIU/mL need additional vaccine doses. 1

Hemodialysis patients: Require annual anti-HBs testing, with booster doses administered when levels decline to <10 mIU/mL. 1, 5

Immunocompromised persons (HIV-infected, transplant recipients, chemotherapy patients): May need annual anti-HBs testing to assess concentrations. 1, 5

Infants born to HBsAg-positive mothers: Require specific revaccination protocols if anti-HBs is <10 mIU/mL after the primary series. 1

Common Pitfalls to Avoid

  • Do not routinely retest or give booster doses to healthy immunocompetent individuals whose anti-HBs has declined below 10 mIU/mL after initially responding to vaccination 1, 2
  • Do not confuse the protective threshold (≥10 mIU/mL) with assay-specific cutoff values that may differ between laboratories 1
  • Do not delay vaccination while waiting for serologic test results in persons who need both testing and vaccination 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Hepatitis B Immunity and Serologic Test Interpretation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Patients with Hepatitis B Immunity and Non-Reactive RPR

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.